drugset / Trial / NCT02466867

An Open Label Pharmacokinetic Study of Naftin for Tinea Corporis

NCT02466867

Phase 4 Completed 27 enrolled Merz North America, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an open label, multi-center, multi-application pharmacokinetic study in pediatric subjects with tinea corporis.

Timeline

Start
2014-01
Primary completion
2015-10
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Naftifine Other / unclassified 3 g Topical
Subject Naftifine Other / unclassified 4 g Topical

Indications